21 results on '"Toyota J"'
Search Results
2. Determination of the optimum timing of the start of nucleoside analogue by FIB-4 index for hepatitis B patients from the viewpoint of suppressing hepatocarcinogenesis
3. Recurrence of hepatocellular carcinoma in patients with a history of HCC after SVR to DAA for chronic hepatitis C
4. Analysis of Hepatitis B Surface Antigen (HBsAg) Levels Using the Highly Sensitive Lumipulse HBsAg-HQ Assay in Hepatitis B Virus Patients with HBsAg Seroclearance According to the Conventional Assay
5. The Real World Experience of Daclatasvir and Asunaprevir Combination Therapy for More Elderly Patients thanthe Clinical Trial Subjects with Genotype 1b Chronic Hepatitis C
6. P0997 : WFA+-M2BP is a predictive factor for fibrosis progression in NAFLD
7. P1216 EFFICACY AND SAFETY OF SIMEPREVIR PLUS PEG-INTERFERON/RIBAVIRIN THERAPY IN PATIENTS WITH HCV GENOTYPE 1 – COMPARISON WITH TELAPREVIR PLUS PEG-INTERFERON/RIBAVIRIN THERAPY AND PEG-INTERFERON/RIBAVIRIN THERAPY
8. 835 RBV BLOOD CONCENTRATION AT FIRST WEEK OF PEG-IFN/RBV/TVR COMBINATION THERAPY IS A GOOD PREDICTIVE MARKER OF RENAL DYSFUNCTION AND ANEMIA
9. 825 ANALYSIS OF THE OPTIMAL TVR DOSE PER WEIGHT JUDGING FROM ANEMIA DURING PEG-IFN/RBV/TVR COMBINATION THERAPY
10. 14 DUAL ORAL THERAPY WITH THE NS5A INHIBITOR DACLATASVIR (BMS-790052) AND NS3 PROTEASE INHIBITOR ASUNAPREVIR (BMS-650032) IN HCV GENOTYPE 1B-INFECTED NULL RESPONDERS OR INELIGIBLE/INTOLERANT TO PEGINTERFERON/RIBAVIRIN
11. 1193 A DESCRIPTION OF VIROLOGIC ESCAPE IN HCV GENOTYPE 1-INFECTED PATIENTS TREATED WITH DACLATASVIR (BMS-790052) IN COMBINATION WITH RIBAVIRIN AND PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B
12. 1124 2250MG/DAY OF TELAPREVIR DOSAGE IMPAIR THE RIBAVIRIN DOSAGE AND CLINICAL EFFECT OF TRIPLE THERAPY IN THE PATIENTS WITH A LOW TOTAL CLEARANCE OF RIBAVIRIN
13. 1330 IL28B GENOTYPE MAJOR AND RELAPSE OF PREVIOUS PEG-IFN/RBV THERAPY ARE THE CONVINCING PREDICTOR OF SUSTAINED VIROLOGICAL RESPONSE IN TELAPREVIR WITH PEG-IFN/RBV THERAPY
14. 268 RELATIONSHIP OF SERUM IP-10 LEVELS WHICH REFLECTS HEPATIC INTERFERON STIMULATING GENE INDUCTION AND ANTIVIRAL EFFECT OF PEG/RBV COMBINATION THERAPY IN PATIENT WITH CHRONIC HEPATITIS C
15. 703 LONG TERM EFFICACY, SAFETY AND RESISTANCE ANALYSES OF ENTECAVIR (ETV) TREATMENT IN JAPANESE NUCLEOSIDE-NAIVE PATIENTS WITH CHRONIC HEPATITIS B (CHB)
16. 799 TIMING OF HCV NEGATIVITY AND POSSIBLE SVR MAY BE PREDICTABLE BY HCVRNA LEVELS MEASURED WITH TAQMAN HCV IN EARLY TREATMENT PHASE
17. Comparison of clinical features of acute hepatitis caused by hepatitis E virus (HEV) genotypes 3 and 4 in Sapporo, Japan
18. P.109 Efficacy and safety of entecavir and lamivudine in japanese adult patients with chronic hepatitis B infection: a phase 2 clinical trial
19. Efficacy of argon plasma coagulation for gastric antral vascular ectasia associated with chronic liver disease
20. Impact of daily high-dose IFNα-2b plus ribavirin combination therapy on reduction of ALT levels in patients with chronic hepatitis C with genotype 1 and high HCV RNA levels
21. Analysis of the prognosis of hepatocellular carcioma, in terms of the optimal time of live donor liver transplantation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.